Search

everythinglearnresearchcommunity

for

Search:↓

User added RU58841 to their hair loss treatment and experienced quick results. Others also reported positive effects, but one user experienced chest pains as a side effect.

The user saw significant hair regrowth using topical minoxidil and finasteride, even on areas not directly treated. They used local Algerian products with 5% minoxidil and 0.1% finasteride and reported no side effects.

RU58841 remains active for several hours after application, and it's suggested to wait a few hours before washing it off to maintain its effectiveness. There is a concern about potential transfer to others if they touch the hair shortly after application.

PP405, a promising hair loss treatment, is expected to be available by 2027, with faster trials due to its topical nature. Users are eager for its release, comparing it to existing treatments like minoxidil and finasteride, but remain cautious about its long-term effectiveness.

The user is using dutasteride and minoxidil for hair loss and noticed new hair growth after initially thinking there was no progress. Encouragement was given to continue the treatment as it takes time to see full results.

A user discusses using dermastamping for hair loss and questions the timing of applying a mixture of peppermint oil, spearmint oil, rosemary oil, and castor oil due to their anti-inflammatory effects. They wonder if waiting 10 hours after stamping would be more effective.

The conversation is about the anticipated results of Pelage's Phase 2a clinical trial for their topical hair loss treatment, PP405. Users speculate on when the results will be available, noting that delays might indicate less successful outcomes.

A 42-year-old user shares progress on hair loss treatment using finasteride, topical minoxidil, and dermarolling. They seek advice on obtaining Minoxidil pills in Europe.

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

The conversation discusses the importance of early action in various aspects of life such as healthy eating, skincare, fitness, sleep, financial planning, and career development to prevent future health issues, regret, and financial hardship. Specific treatments mentioned include using sunscreen and tretinoin for anti-aging skincare.

User asks if HMI 115 hasn't done phase 1 for AGA in humans. Conversation includes treatments Min, Fin, and RU.

The conversation is about individuals considering waiting for Breezula to treat hair loss instead of using Finasteride due to concerns about side effects. Some are opting for Finasteride now, while others are wary of its impact on neurosteroids.

An 18-year-old experienced severe side effects, including heart palpitations and high blood pressure, after using RU58841 once, leading to a referral to cardiology for suspected left ventricular hypertrophy. The user regrets using RU58841 and seeks advice on recovery, while others suggest preexisting conditions or genetic predispositions may be factors.

The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

People are discussing the potential of a new hair loss treatment, pp405, and its approval timeline, comparing it to existing treatments like Minoxidil and finasteride. There is skepticism about its effectiveness and concerns about the time it will take for approval and availability, especially in Europe.

The conversation is about the long-term safety trial results for pyrilutamide, which are expected soon. Treatments mentioned include Minoxidil, finasteride, and RU58841.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

PP405 is anticipated as a future treatment for dormant hair follicles, but its effectiveness and safety are uncertain. Current treatments include oral minoxidil and microneedling, with some avoiding finasteride due to side effects.

PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.

The 24-hour waiting period after dermarolling before applying minoxidil is unnecessary. New research supports the simultaneous application of minoxidil with microneedling for better hair growth results.

A user humorously questions if finasteride can cause hair regrowth in just 10 seconds. Responses include jokes about unrealistic expectations, suggestions to try minoxidil and microneedling, and discussions on hair loss treatments.

The conversation humorously suggests that the hair loss industry, referred to as "Big Bald," deliberately delays a cure to profit from ongoing treatments like minoxidil, finasteride, and dutasteride. Participants debate whether a cure would be more profitable than current treatments, with some suggesting that the industry prefers continuous treatments for sustained profit.

The conversation discusses hair loss treatments, focusing on a new slow-release oral minoxidil compared to topical minoxidil and finasteride. The results show that twice-daily dosing of the new treatment is slightly more effective than once-daily, but concerns about cost, side effects, and the accuracy of reported results remain.

The conversation discusses whether to wait 24 hours before applying minoxidil after using a .5 mm dermaroller for hair loss treatment. The specific treatments mentioned are microneedling, minoxidil, and dermarolling.

Finasteride may take over two years to show results and can cause side effects like sexual dysfunction and emotional changes. Alternatives such as dutasteride and minoxidil are discussed, with varying effectiveness and side effects.

The user has not seen results from various hair loss treatments including finasteride, dutasteride, minoxidil, and others over several years and is considering adding RU58841 and starting hormone replacement therapy. They are also experiencing anxiety and contemplating moving to a more accepting environment for their nonbinary identity.

The user is experiencing side effects from fluridil after switching from finasteride due to severe side effects. They are uncertain whether to continue with fluridil, considering it might be their body adjusting, a nocebo effect, or a permanent issue.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

The conversation is about a user seeking feedback on hair regrowth progress after two months of using finasteride, minoxidil, ketoconazole shampoo, dermastamping, and iron supplements. Most responses suggest that two months is too early to see significant results and recommend patience, with noticeable changes typically occurring around 4-6 months.